AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02061774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
Study NCT01529047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Printed or electronic form containing personalized information about health-relevant behaviors
Study NCT00889408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT2219ARL
Description: anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
Study NCT03154593 — intervention group
Intervention type: OTHER
Intervention: Stage 2 - Bariatric Surgery
Description: This observational study follows patients after routine bariatric surgery.
Study NCT03764007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluorocholine
Description: Given intravenously
Study NCT03764007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
Study NCT01115361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family planning for postpartum women
Description: A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants.
Study NCT02764333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPIV200
Study NCT02764333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT00817544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
Study NCT01428271 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Description: The confirmation of the real site of the sacral hiatus by ultrasonography
Study NCT00957229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: capsule, 150 mg, one pill daily, 18 months
Study NCT00957229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0449
Description: capsule, 150 mg, one pill daily, 18 months
Study NCT00413491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR mammography
Description: MR mammography
Study NCT00413491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR
Description: MR
Study NCT01757509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling.
Study NCT01564875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvast CR
Description: Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
Study NCT01564875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zocor
Description: Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
Study NCT03864484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad Application + Usual Rehabilitation
Description: The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
Study NCT03864484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation
Description: The control group receives usual rehabilitation.
Study NCT01250002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will receive the same volume of saline infusion.
Study NCT01250002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
Study NCT00651885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil dienthanolmine sustained release
Description: UT-15C SR 1mg tablet
Study NCT00651885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05246553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the vestibular system
Description: Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
Study NCT05246553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation of the auditory system
Description: A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
Study NCT05246553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the auditory system
Description: A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
Study NCT05246553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral vestibulopathy Patients (BV)
Description: Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
Study NCT05246553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral vestibulopathy Patients (UV)
Description: Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
Study NCT02430181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyl transferase inhibitor
Study NCT04431635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib IV: day 1, 8, 15 every 28 days
Study NCT04431635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
Study NCT02430181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: immunomodulator
Study NCT02430181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: CYP 3A4 inhibitor, lonafarnib booster
Study NCT02588482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Auditory stimulations during electroencephalography recording
Study NCT02588482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional electroencephalography
Description: Auditory stimulations during electroencephalography recording
Study NCT03054220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG
Study NCT03054220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 10 mg
Study NCT04431635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
Study NCT04478708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
Study NCT04478708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
Study NCT03088852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate 100 MG
Description: initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
Study NCT02073136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with phosphate containing additives
Study NCT02073136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet without phosphate containing additives
Study NCT03935841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-OHB salt (NaCl)
Description: 36 gram 3-OHB salt diluted in 500 ml sterile water
Study NCT03054220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg
Study NCT03054220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Study NCT00459264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid oral solution 2.5mg/5ml daily for up to 3 years
Study NCT00459264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for folic acid oral solution (2.5mg/5ml)
Study NCT01188486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Standard of care diagnostic radiotherapy procedure
Study NCT01188486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
Study NCT01188486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberknife
Description: Linear accelerator for producing high energy x-rays for radiation therapy.
Study NCT01188486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy
Description: Linear accelerator for producing high energy x-rays for radiation therapy.
Study NCT01188486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True Beam
Description: Linear accelerator for producing high energy x-rays for radiation therapy.
Study NCT01188486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
Study NCT04811378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HaemoCer
Description: Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
Study NCT00434954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide twice daily (BID)
Description: subcutaneous injection (5 mcg or 10 mcg), twice a day
Study NCT00434954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: premixed insulin aspart twice daily (BID)
Description: subcutaneous injection (titrated appropriately), twice a day
Study NCT01175460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Nedaplatin
Description: nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
Study NCT00002651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally
Study NCT00002651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally
Study NCT00002651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Description: Given subcutaneously
Study NCT00002651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously
Study NCT00002651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
Study NCT03935841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB salt (NaCl)
Description: 36 gram 3-OHB salt diluted in 500 ml sterile water
Study NCT04439110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study NCT01649050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT01649050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01787422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional versus Telemedicine office visit
Study NCT01787422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional versus Telemedicine office visit
Study NCT00400738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir, lopinavir, ritonavir
Description: arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
Study NCT01188486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
Study NCT01429779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Movicol
Description: Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
Study NCT01813903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified dietary counseling
Description: The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
Study NCT01813903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
Study NCT03035656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of Ropivaciane via epidural injection intra-operatively
Study NCT03035656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline via epidural injection intra-operatively
Study NCT03795701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda®
Description: Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
Study NCT03795701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
Study NCT03646331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin Reference product
Description: Reference product
Study NCT03646331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Test product (new formulation tablet)
Study NCT01710514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999913 vaginal tablet
Study NCT04675463 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BGF Inhalation Aerosphere
Description: Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
Study NCT04675463 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GFF Inhalation Aerosphere
Description: Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
Study NCT04044664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules.
Study NCT04044664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-783
Description: NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study NCT02648529 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)
Study NCT02648529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)
Study NCT02648529 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: functional MRI (fMRI)
Description: fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups.
Study NCT02648529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional MRI (fMRI)
Description: fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups.
Study NCT02648529 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological assessment
Description: Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.